Evidence map›Paper›PMID 35681781›Full record

ArticleCancers2022

In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series.

Saira Sanjida, Brigid Betz-Stablein, Victoria Atkinson, Monika Janda, Ramez Barsoum, Harrison Aljian Edwards, Frank Chiu, My Co Tran, H Peter Soyer, Helmut Schaider

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Saira SanjidaCentre for Health Services Research, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Brigid Betz-StableinThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.ORCID 0000-0003-3876-501X
Victoria AtkinsonCancer Care Services, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia.
Monika JandaCentre for Health Services Research, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Ramez BarsoumThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Harrison Aljian EdwardsThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Frank ChiuThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.
My Co TranThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.
H Peter SoyerThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Helmut SchaiderThe University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia.ORCID 0000-0003-3195-2517
The University of Queensland · AUPrincess Alexandra Hospital · AU

Funding

Medical Research Future Fund - Next Generation Clinical Researcher's Program Practitioner Fellowship APP1137127National Health and Medical Research Council APP1099021National Health and Medical Research Council TRIP Fellowship APP1151021
6 · The paper itself

Abstract

Immunotherapies and targeted therapies have shown significant benefits for melanoma survival in the clinical trial setting. Much less is known about the characteristics and associated outcomes of those receiving such therapies in real-world settings. This study describes the characteristics of patients with advanced melanoma receiving immuno- and/or targeted therapies in a real-world setting. This prospective cohort study enrolled participants aged >18 years, diagnosed with advanced melanoma and currently undergoing immuno- and/or targeted therapies outside a clinical trial for follow-up with three-dimensional (3D) total-body imaging. Participants (n = 41) had a mean age of 62 years (range 29−86), 26 (63%) were male and the majority (n = 26, 63%) had ≥2 comorbidities. After a median of 39 months (range 1−52) follow-up, 59% (n = 24/41) of participants were alive. Despite multiple co-morbidities, the survival of participants with advanced melanoma treated using immuno- and/or targeted therapies was similar or better in our real-world setting compared to those treated in clinical trials using similar therapies. Larger studies powered to evaluate phenotypic and socio-economic characteristics, as well as specific comorbidities associated with survival in a real-world setting, are required to help determine those who will most benefit from immuno- and/or targeted therapies.

Indexed as

advanced melanomaimmunotherapyreal-world settingsurvivaltargeted therapy

Identifiers

PMID35681781
PMCPMC9179437
OpenAlexW4281997854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.